Published in N Engl J Med on June 08, 2017
Pembrolizumab for Advanced Urothelial Carcinoma. N Engl J Med (2017) 0.75
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. N Engl J Med (2017) 4.67